Skip to content
Companies

BRT Biotechnologies

Macrocyclic peptide libraries for drug screening

Raised to date

$607K

of $607K offered across 1 Form D filing

Investors
12
Last filed
May 8, 2026

About

BRT Biotechnologies is a drug-discovery tools company that designs and manufactures large, structurally diverse macrocyclic peptide libraries for pharmaceutical and biotech screening programs. Its proprietary BRiTeCycle platform uses spatially addressed synthesis to build libraries of 10,000 to 1 million non-canonical macrocycles in weeks rather than months or years, drawing on more than 60 unique alpha-, beta- and gamma-amino acid building blocks including N-alkylated and cyclic structures. The libraries are aimed at hard-to-drug targets in oncology and infectious disease and are sold both directly and through distribution partner Chem-Impex. The company was founded in 2021 by Pomona College chemist Jane Liu and Gregory Copeland and is based in Claremont, California.

Spatially addressed synthesis means every macrocycle's identity is known by position, so libraries can be screened directly in phenotypic and mass-spectrometry workflows without deconvolution, and refined roughly 4x faster than conventional library approaches.

Funding

  • Security to be acquiredFiled May 8, 2026Form D
    $607K/ $607K

Product

BRiTeCycle Macrocyclic Peptide (MCP) Libraries

Drug discovery compound libraries

Customizable libraries of non-canonical macrocyclic peptides built on the proprietary BRiTeCycle platform, offered in catalog sizes such as 2,300 and 10,000+ macrocyclic hexapeptides and scalable to libraries of up to one million compounds.

  • Libraries of 10,000 to 1,000,000 macrocycles synthesized in weeks
  • 60+ unique alpha-, beta- and gamma-amino acid building blocks, including N-alkylated and cyclic residues
  • Spatially addressed synthesis for precise control over molecular design and iteration

Built for

Pharmaceutical and biotech discovery teams working early-stage programs against hard-to-drug targets, particularly in oncology and infectious disease

People on file